Your browser is no longer supported. Please, upgrade your browser.
Settings
PULM [NASD]
Pulmatrix, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own0.67% Shs Outstand36.16M Perf Week-5.45%
Market Cap49.90M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float34.03M Perf Month-16.39%
Income-19.30M PEG- EPS next Q-0.10 Inst Own24.50% Short Float2.32% Perf Quarter-54.62%
Sales12.60M P/S3.96 EPS this Y45.40% Inst Trans22.89% Short Ratio0.31 Perf Half Y-21.48%
Book/sh0.64 P/B1.41 EPS next Y-10.80% ROA-52.50% Target Price- Perf Year-42.12%
Cash/sh0.57 P/C1.57 EPS next 5Y- ROE-114.50% 52W Range0.84 - 3.04 Perf YTD-24.12%
Dividend- P/FCF- EPS past 5Y53.90% ROI- 52W High-70.30% Beta1.40
Dividend %- Quick Ratio3.90 Sales past 5Y60.10% Gross Margin- 52W Low7.42% ATR0.08
Employees20 Current Ratio3.90 Sales Q/Q17.60% Oper. Margin-77.50% RSI (14)37.62 Volatility8.03% 7.73%
OptionableNo Debt/Eq0.00 EPS Q/Q59.70% Profit Margin- Rel Volume0.22 Prev Close0.86
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume2.57M Price0.90
Recom- SMA20-6.27% SMA50-26.27% SMA200-29.23% Volume567,615 Change5.00%
Feb-09-18Initiated H.C. Wainwright Buy $5
May-11-21 04:35PM  
Apr-15-21 09:15AM  
Apr-12-21 05:41PM  
09:00AM  
Mar-23-21 09:05AM  
Mar-04-21 09:15AM  
Feb-16-21 01:30PM  
Feb-11-21 12:24AM  
Nov-12-20 09:00AM  
Nov-09-20 01:39PM  
Oct-21-20 09:00AM  
Sep-30-20 08:30AM  
Sep-29-20 08:30AM  
Sep-22-20 08:30AM  
Aug-07-20 09:00AM  
Jul-08-20 08:30AM  
Jun-26-20 09:00AM  
May-27-20 09:00AM  
May-14-20 09:00AM  
Apr-29-20 10:02AM  
Apr-16-20 05:25PM  
08:30AM  
Mar-26-20 09:00AM  
Jan-31-20 07:20AM  
Jan-30-20 08:00AM  
Jan-16-20 12:05PM  
Jan-06-20 08:58AM  
Jan-03-20 09:55AM  
Jan-02-20 08:51AM  
Nov-04-19 09:15AM  
Nov-01-19 09:00AM  
Sep-18-19 09:30AM  
Aug-19-19 09:25AM  
Aug-05-19 09:00AM  
Jun-07-19 10:25AM  
Jun-06-19 06:42AM  
May-16-19 09:10AM  
May-15-19 09:00AM  
Apr-15-19 09:00AM  
Apr-08-19 04:29PM  
Apr-03-19 09:30PM  
Apr-01-19 05:33PM  
02:34PM  
09:00AM  
Mar-14-19 09:45AM  
Mar-12-19 12:22PM  
Mar-08-19 01:00PM  
Feb-19-19 09:00AM  
Feb-12-19 09:30AM  
Feb-08-19 07:00AM  
Feb-07-19 09:00AM  
Feb-06-19 12:15PM  
09:00AM  
Feb-05-19 12:45PM  
11:14AM  
Jan-31-19 01:24PM  
Jan-30-19 09:52PM  
04:01PM  
Jan-28-19 11:27PM  
04:18PM  
Nov-29-18 05:00AM  
Nov-21-18 09:30AM  
Nov-15-18 09:30AM  
Nov-14-18 04:30PM  
Sep-18-18 11:45AM  
Sep-17-18 09:35AM  
Aug-28-18 10:00AM  
Aug-03-18 09:00AM  
Jul-23-18 10:13AM  
Jul-20-18 07:20AM  
Jul-17-18 09:00AM  
Jun-25-18 08:30AM  
Jun-13-18 09:35AM  
Jun-07-18 09:30AM  
Jun-04-18 07:40AM  
07:20AM  
May-25-18 12:49PM  
May-17-18 09:35AM  
May-11-18 09:00AM  
Mar-29-18 12:02AM  
Mar-13-18 04:42PM  
Mar-09-18 09:46AM  
Feb-12-18 09:35AM  
Jan-29-18 08:00AM  
Jan-28-18 11:01PM  
Jan-25-18 10:30AM  
Jan-24-18 12:00PM  
Jan-22-18 10:25AM  
Dec-19-17 11:45AM  
Dec-04-17 05:10PM  
Nov-29-17 08:47AM  
Nov-14-17 01:00PM  
Nov-09-17 04:30PM  
Oct-31-17 11:00AM  
Oct-30-17 09:45AM  
Oct-24-17 10:00AM  
Oct-11-17 02:14PM  
Oct-03-17 09:45AM  
Sep-27-17 08:10AM  
Sep-21-17 09:50AM  
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.